% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Gambichler:277134,
      author       = {T. Gambichler and J. C. Becker$^*$ and L. Susok and R.
                      Käpynen and N. Abu Rached},
      title        = {{M}odel for {E}nd-{S}tage {L}iver {D}isease {C}orrelates
                      with {D}isease {R}elapse and {D}eath of {P}atients with
                      {M}erkel {C}ell {C}arcinoma.},
      journal      = {Cancers},
      volume       = {15},
      number       = {12},
      issn         = {2072-6694},
      address      = {Basel},
      publisher    = {MDPI},
      reportid     = {DKFZ-2023-01296},
      pages        = {3195},
      year         = {2023},
      abstract     = {Merkel cell carcinoma (MCC) is a highly malignant skin
                      tumor that occurs mainly in elderly and/or immunosuppressed
                      patients. MCC prognosis has been significantly improved by
                      the introduction of immune checkpoint inhibitor treatment.
                      Recently, blood-based biomarkers have been investigated that
                      can potentially predict the outcome of MCC patients. In this
                      context, parameters of liver scores have not yet been
                      investigated. We retrospectively recruited 47 MCC patients
                      with available relevant laboratory data at primary
                      diagnosis. At this time, we investigated blood-based scores
                      as follows: model for end-stage liver disease (MELD),
                      aspartate aminotransferase/platelet count ratio index
                      (APRI), and the alanine transaminase/aspartate
                      aminotransferase ratio (De Ritis ratio). MCC relapse was
                      negatively correlated with the De Ritis score (r = -0.3, p =
                      0.024) and positively correlated with the MELD score (r =
                      0.3, p = 0.035). Moreover, MCC-specific death positively
                      correlated with CCI score (r = 0.4, p = 0.01) and MELD score
                      (r = 0.4, p = 0.003). In multivariable analysis, the MELD
                      score remained in the regression model as significant
                      independent predictor for MCC relapse (hazard ratio: 1.16
                      $(95\%$ CI 1.04 to 1.29; p = 0.008) and MCC-specific death
                      (hazard ratio: 1.2 $(95\%$ CI 1.04 to 1.3; p = 0.009). We
                      observed for the first time that the MELD score appears to
                      independently predict both MCC relapse and MCC-specific
                      death. These results should be further investigated in
                      larger prospective studies.},
      keywords     = {APRI-score (Other) / De Ritis (Other) / MCC (Other) / MELD
                      (Other) / biomarkers (Other) / carcinoma (Other) / liver
                      (Other) / neuroendocrine (Other) / skin cancer (Other) /
                      tumor metabolism (Other)},
      cin          = {ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37370805},
      doi          = {10.3390/cancers15123195},
      url          = {https://inrepo02.dkfz.de/record/277134},
}